

Press Releases

All Years ▾
<input type="text" value="Search"/>
<input type="button" value="Go"/>

[Advanced Search](#)

MAR 7, 2018

[Perrigo to Present at Upcoming Investor Conferences](#)

MAR 1, 2018

[Perrigo Files Form 10-K With SEC; Will Host Fourth Quarter And Calendar Year 2017 Financial Results Conference Call On March 2, 2018](#)

MAR 1, 2018

[Perrigo Company plc Reports Fourth Quarter & Calendar Year 2017 Financial Results](#)

FEB 27, 2018

[Perrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results](#)

Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018

FEB 20, 2018

[Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%](#)

FEB 20, 2018

[Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer](#)

FEB 15, 2018

[Perrigo Announces Quarterly Dividend](#)

FEB 8, 2018

[Perrigo To Release Fourth Quarter And Calendar Year 2017 Financial Results On February 27, 2018](#)

JAN 30, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream, 1%](#)

JAN 26, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel](#)

JAN 24, 2018

[Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream](#)

JAN 24, 2018

[Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo® Gel](#)

JAN 8, 2018

[Perrigo Appoints Uwe Röhrhoff As President & Chief Executive Officer](#)

- Uwe Röhrhoff, former Chief Executive Officer at Gerresheimer AG, appointed President, CEO and board member effective January 15, 2018

JAN 3, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa® Ophthalmic Solution 0.07%](#)

JAN 2, 2018

[Perrigo To Present At The 36th Annual J.P. Morgan Healthcare Conference](#)

NOV 27, 2017

[Perrigo Announces the Launch of an AB Rated Generic Version of Mycolog® II Cream](#)

NOV 27, 2017

[Perrigo Announces the Launch of an AB Rated Generic Version of Exalgo® 32mg Extended Release Tablets](#)

NOV 21, 2017

[Perrigo Company Completes Divestiture Of API Business For \\$110 Million](#)

NOV 10, 2017

[Perrigo Company to Present at the Stifel 2017 Healthcare Conference](#)

NOV 9, 2017

[Perrigo Company plc Reports Third Quarter 2017 Financial Results](#)

NOV 2, 2017

[Perrigo Company plc Announces Quarterly Dividend](#)

NOV 2, 2017

[Perrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato® Gel 0.05%](#)

OCT 26, 2017

[Perrigo To Release Third Quarter 2017 Financial Results On November 9, 2017](#)

OCT 26, 2017

[Perrigo Announces Patent Litigation Settlement for the Generic Version of Onexton® Gel](#)

OCT 24, 2017

[Perrigo Announces Tentative FDA Approval For A First-To-File Generic Version Of Picato® Gel .015%](#)

Show per
page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [...](#) [38](#) [»](#)



<https://investor.perrigo.com/press-releases?l=25&o=250>